A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives

European Journal of Cancer and Clinical Oncology - Tập 25 Số 4 - Trang 711-720 - 1989
Emile E. Voest1, Hans C. van Houwelingen2, J.P. Neijt1
1Utrecht University Hospital, Department of Oncology, Catharijnesingel 101, 3511 GV Utrecht, The Netherlands
2Leiden University, Department of Medical Statistics, The Netherlands

Tóm tắt

Từ khóa


Tài liệu tham khảo

Young, 1978, Advanced ovarian adenocarcinoma, a prospective clinical trial of melphalan (L-PAM) vs. combination chemotherapy, N Engl J Med, 299, 1261, 10.1056/NEJM197812072992301

Cohen, 1983, Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical endstaging (second-look operation), Am J Obstet Gynecol, 145, 955, 10.1016/0002-9378(83)90849-9

Griffiths, 1975, Surgical resection of tumorbulk in the primary treatment of ovarian carcinoma, Natl Cancer Inst Monogr, 42, 101

Decker, 1975, Prognostic importance of histologic grading in ovarian carcinoma, Natl Cancer Inst Monogr, 42, 9

Ozols, 1980, Advanced ovarian cancer, 45, 572

Rodenburg, 1987, Tumor ploidy as a major of prognostic factor in advanced ovarian cancer, Cancer, 59, 317, 10.1002/1097-0142(19870115)59:2<317::AID-CNCR2820590225>3.0.CO;2-4

Redman, 1986, Prognostic factors in advanced ovarian carcinoma, J Clin Oncol, 4, 515, 10.1200/JCO.1986.4.4.515

Day, 1975, Epithelial carcinoma of the ovary: prognostic importance of histologic grade, Natl Cancer Inst Monogr, 42, 15

Glass, 1976, Primary, secondary and meta-analysis of research, Educ Res, 5, 3, 10.3102/0013189X005010003

Sacks, 1987, Meta-analysis of randomized controlled trials, N Engl J Med, 316, 450, 10.1056/NEJM198702193160806

Edmonson, 1985, Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas, Cancer Treat Rep, 69, 1243

Neijt, 1984, Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma, Lancet, 15, 594, 10.1016/S0140-6736(84)90594-4

Wiltshaw, 1986, A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma, J Clin Oncol, 4, 722, 10.1200/JCO.1986.4.5.722

Wils, 1986, Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide in stage III–IV epithelial ovarian carcinoma, J Clin Oncol, 4, 1068, 10.1200/JCO.1986.4.7.1068

Schwartz, 1981, Combination chemotherapy for advanced ovarian cancer, 65, 137

Carmo-Pereira, 1981, Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF), Cancer, 48, 1947, 10.1002/1097-0142(19811101)48:9<1947::AID-CNCR2820480906>3.0.CO;2-M

Omura, 1983, A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus Adriamycin plus cyclophosphamide in ovarian carcinoma, Cancer, 51, 783, 10.1002/1097-0142(19830301)51:5<783::AID-CNCR2820510506>3.0.CO;2-Z

Williams, 1982, Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination, Cancer, 49, 1778, 10.1002/1097-0142(19820501)49:9<1778::AID-CNCR2820490908>3.0.CO;2-Z

Edwards, 1983, A prospective randomized clinical trail of melphalan and cis-platinum versus hexamethylmelamine, Adriamycin and cyclophosphamide in advanced ovarian cancer, Gynecol Oncol, 15, 261, 10.1016/0090-8258(83)90082-3

Wharton, 1982, Single agent Adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma, Gynecol Oncol, 14, 262, 10.1016/0090-8258(82)90098-1

Conte, 1986, A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide in advanced ovarian cancer, J Clin Oncol, 4, 965, 10.1200/JCO.1986.4.6.965

Vogl, 1983, Cisplatin based combination chemotherapy for advanced ovarian cancer, Cancer, 51, 2024, 10.1002/1097-0142(19830601)51:11<2024::AID-CNCR2820511111>3.0.CO;2-I

De Palo, 1981, Prospective study with Hexa-CAF combination in ovarian carcinoma, Cancer Chemother Pharmacol, 5, 157, 10.1007/BF00258473

White, 1981, Continuous versus intermittent treatment with treosulfan in advanced ovarian cancer, 19

Klaassen, 1979, Cancer Treat Rep, 63, 289

Young, 1974, Advanced ovarian adenocarcinoma, 2, 489

Creasman, 1979, Chemo-immunotherapy in the management of primary stage III ovarian cancer; a Gynecologic Oncology Group Study, Cancer Treat Rep, 63, 319

Geisler, 1976, The treatment of advanced ovarian carcinoma with high dose intravenous cyclophosphamide, Gynecol Oncol, 4, 43, 10.1016/0090-8258(76)90006-8

Bruckner, 1983, Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer, Am J Obstet and Gynecol, 145, 653, 10.1016/0002-9378(83)90569-0

Abdulla, 1983, Chemotherapy of advanced ovarian carcinoma: use of intravenous treosulfan in previously untreated disease

Decker, 1983, Cyclophosphamide plus cis-platinum in combination: treatment program for stage III and IV ovarian carcinoma, Obstet Gynecol, 60, 481

Bruckner, 1981, Improved chemotherapy for ovarian cancer with cis-diammine-dichloroplatinum and Adriamycin, Cancer, 47, 2288, 10.1002/1097-0142(19810501)47:9<2288::AID-CNCR2820470931>3.0.CO;2-3

Gershenson, 1981, Single agent cis-platinum therapy for advanced ovarian cancer, Obstet Gynecol, 58, 487

Barlow, 1980, High-dose methotrexate with ‘rescue’ plus cyclophosphamide as initial chemotherapy in ovarian adenocarcinoma, Cancer, 46, 1333, 10.1002/1097-0142(19800915)46:6<1333::AID-CNCR2820460606>3.0.CO;2-3

Piccart, 1987, Advanced ovarian cancer: 3 year-results of a 6–8 month, 2-drug cisplatin-containing regimen, Eur J Cancer Clin Oncol, 23, 631, 10.1016/0277-5379(87)90258-6

Bruckner, 1986

Williams, 1985, Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial, J Clin Oncol, 3, 1455, 10.1200/JCO.1985.3.11.1455

Aabo, 1985, A randomized study of single agent versus combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma, Eur J Cancer Clin Oncol, 21, 475, 10.1016/0277-5379(85)90040-9

De Gramont, 1985, Adriamycin and cisplatin in advanced ovarian cancer, Eur J Cancer Clin Oncol, 21, 665, 10.1016/0277-5379(85)90262-7

Sessa, 1985, Hexamethyl-melamine, Adriamycin and cyclophosphamide (HAC) versus cis-dichlorodiammine platinum, Adriamycin and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized trial, Cancer Chemother Pharmacol, 14, 222, 10.1007/BF00258120

Louie, 1986, Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma, J Clin Oncol, 4, 1579, 10.1200/JCO.1986.4.11.1579

Neijt, 1987, Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma, J Clin Oncol, 5, 1157, 10.1200/JCO.1987.5.8.1157

Young, 1984, Alternating combination chemotherapy for stages III and IV ovarian carcinoma, J Clin Oncol, 2, 1317, 10.1200/JCO.1984.2.12.1317

Omura, 1986, A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma, Cancer, 57, 1725, 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J

Ehrlich, 1983, Treatment of advanced epithelial ovarian cancer using cisplatin, Adriamycin and cytoxan—the Indiana University experience, Clin Obstet Gynecol, 10, 325

Bell, 1982, Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum, Austr NZ J Med, 12, 245, 10.1111/j.1445-5994.1982.tb02469.x

Wharton, 1979, Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer, Am J Obstet Gynecol, 133, 833, 10.1016/0002-9378(79)90120-0

Neijt, 1988, Long-term results of combination chemotherapy in advanced ovarian cancer, 7, 136

Griffiths, 1979, Role of cytoreductive surgical treatment in the management of advanced ovarian cancer, Cancer Treat Rep, 63, 235

Edmonson, 1979, Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease, Cancer Treat Rep, 63, 241

Levin, 1987, Dose intensity analysis of chemotherapy regimens in ovarian carcinoma, J Clin Oncol, 5, 756, 10.1200/JCO.1987.5.5.756